Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alt-2074 SCHEMBL29379070 | 1.00 | BCHE (0.31) | BCHEACHEPDK2PDK4 | |
| SCHEMBL6956152 | 0.69 | HTR2A (0.41) | BCHEPDK2PDK4 | |
| SCHEMBL888127 | 0.68 | BCHE (0.34) | BCHEACHEPDK2PDK4 | |
| SCHEMBL1031209 | 0.64 | PDK2 (0.42) | PDK2PDK4 | |
| SCHEMBL29384370 | 0.64 | PDK2 (0.42) | PDK2PDK4 | |
| Hydrochloric Acid SCHEMBL2482151 | 0.63 | PDK2 (0.41) | PDK2PDK4 | |
| SCHEMBL329676 | 0.61 | HTR2A (0.42) | BCHE | |
| SCHEMBL29588076 | 0.61 | HTR2A (0.42) | BCHE | |
| SCHEMBL38664070 | 0.61 | PDK2 (0.39) | PDK2PDK4 | |
| SCHEMBL1451116 | 0.61 | PDK2 (0.31) | PDK2PDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| EP-1393277-B1 | USE OF NF-Kappa-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON INC (CH) | 2006-07-19 | — | — | EP | claimed |
| WO-2004098510-A2 | CYSTIC FIBROSIS THERAPY | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2004-11-18 | — | — | WO | claimed |
| EP-1393277-A1 | USE OF NFKB INHIBITORS TO TREAT DRY EYE DISORDERS | Alcon, Inc. (CH) | 2004-03-03 | — | — | EP | claimed |
| US-6696453-B2 | ADMINISTERING NF- KAPPA B INHIBITORS FOR THERAPY OF DRY EYES | ALCON, INC. (CH) | 2004-02-24 | — | — | US | claimed |
| WO-2002095704-A9 | USE OF NF-KAPPA-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON INC (CH) | 2003-02-27 | — | — | WO | claimed |
| US-20030008854-A1 | Use of NF-kappabeta inhibitors to treat dry eye disorders | ALCON, INC. | 2003-01-09 | — | — | US | claimed |
| WO-2002095704-A1 | USE OF NF-KAPPA-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON, INC. (CH) | 2002-11-28 | — | — | WO | claimed |
| US-9155724-B2 | Combination methods for treatment of disease | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-10-13 | — | — | US | disclosed |
| US-8501478-B2 | Trehalose click polymers for delivery of biologically active molecules | UNIVERSITY OF CINCINNATI (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013040445-A1 | ARRAYS FOR CELL-BASED SCREENING AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-02-28 | — | — | US | disclosed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | disclosed |
| EP-1379540-A2 | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB PATHWAY | Bristol-Myers Squibb Company (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030224486-A1 | Polynucleotides and polypeptides associated with the NF-kB pathway | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2002095704-A9 | USE OF NF-KAPPA-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON INC (CH) | 2003-02-27 | — | — | WO | disclosed |
| WO-2002095704-A1 | USE OF NF-KAPPA-B INHIBITORS TO TREAT DRY EYE DISORDERS | ALCON, INC. (CH) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002086076-A2 | POLYNUCLEOTIDES AND POLYPEPTIDES ASSOCIATED WITH THE NF-KB PATHWAY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | BCHE 998/4885ACHE 815/4885PDK2 2223/4885 |
| US-20130053415-A1 | COMBINATION METHODS FOR TREATMENT OF DISEASE | NFATC1, IRF3, BCOR | BCHE 4028/4885ACHE 4795/4885PDK2 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.